Advanced therapies require highly-sophisticated advance planning. For long-term success, transformative cell and gene therapies rely on a risk-based understanding of the supply chain, with all aspects mapped out early. Recent draft guidance from regulatory authorities stresses early end-to-end systems thinking and data management capabilities. A commercially-minded approach to each clinical phase will help create viable commercial supply chains and patient journeys from the beginning.
This white paper provides valuable commercial-phase insights from industry veterans with deep commercialization experience and discusses how these lessons can be applied to clinical-phase therapies to help drive advancement and success.
- Gain an understanding of the evolving nature of each development phase in advanced therapies.
- Learn how commercial success brings more innovation.
- Read more about how the advanced therapies industry is increasingly comfortable with clinical and process development stages.